Individualized treatment based on single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
Background/Aims The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we eva...
Main Authors: | Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, Osamu Takeuchi, Toshifumi Hibi |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of Intestinal Diseases
2019-04-01
|
Series: | Intestinal Research |
Subjects: | |
Online Access: | http://www.irjournal.org/upload/pdf/ir-2018-00117.pdf |
Similar Items
-
Tacrolimus for the Treatment of Ulcerative Colitis
by: Katsuyoshi Matsuoka, et al.
Published: (2015-07-01) -
Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy
by: Ryohei Hayashi, et al.
Published: (2015-07-01) -
Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome.
by: Takahiko Toyonaga, et al.
Published: (2017-01-01) -
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
by: Keiji Yagisawa, et al.
Published: (2019-01-01) -
Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
by: Keiji Yagisawa, et al.
Published: (2020-07-01)